Advertisement

Vaccine Therapy for Gastrointestinal Cancers

  • John L. Marshall
Part of the Cancer Drug Discovery and Development book series (CDD&D)

Abstract

Immune therapies for gastrointestinal (GI) cancers have actually been tested over several decades. Early attempts at immunotherapy focused mostly on the enhancement of the immune response systemically and nonspecifically by the addition of agents such as interferon (IFN), interleukin-2 (IL-2), levamisole, and bacille Calmette-Guérin (BCG) (1). These efforts have not resulted in effective therapies. The more recent work has focused on enhancing the immune system against specific tumor-associated antigen(s) (TAAs). Many vaccine and immune-based therapies are/have been tested that utilize a cancer-specific approach instead of nonspecific enhancement of the immune system. These approaches are attempting to take advantage of our increased understanding of what distinguishes cancer cells from normal cells with the goal of developing effective and nontoxic immune therapies for cancer patients. It will be these therapies on which this chapter will focus.

Keywords

Clin Oncol Costimulatory Molecule Recombinant Vaccinia Virus Vaccine Therapy Advanced Colon Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Marshall JL, Fox E. Vaccine therapy for colorectal cancer. In: Bleiberg H, Kemeny N, Rougier P, Wilke H-J, eds. Colorectal cancer: a clinical guide to therapy. London: Martin Dunitz, 2002:661–672.Google Scholar
  2. 2.
    Maxwell-Armstrong CA, Durrant LG, Scholefield JH. Immunotherapy for colorectal cancer. Am J Surg 1999; 177:344–348.PubMedCrossRefGoogle Scholar
  3. 3.
    Pardo11 DM. Cancer vaccines. Nat Med 1998; 5:525–531.CrossRefGoogle Scholar
  4. 4.
    Ockert D, Schirrmacher V, Beck N, et al. Newcastle disease virus infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res 1996; 2:21–28.PubMedGoogle Scholar
  5. 5.
    Weber CE. Cytokine modified tumor vaccines: an antitumor strategy revisited in the age of molecular medicine. Cancer Nurs 1998; 21:167–177.PubMedCrossRefGoogle Scholar
  6. 6.
    Haspel MV, McCabe RP, Pomato N, et al. Coming full circle in immunotherapy of colorectal cancer: vaccination with autologous tumor cells-to human monoclonal antibodies-to development and application of a generic tumor vaccine. In: Metzgar RS, Mitchell MS, eds. Human tumor antigens and specific tumor therapy. New York: Liss, 1989:335–344.Google Scholar
  7. 7.
    Hoover HC, Surdyke M, Dangel RB, et al. Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer 1985; 55:1236.PubMedCrossRefGoogle Scholar
  8. 8.
    Hoover HC, Brandhurst JS, Peters LC, et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5 year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 1993; 11:390–399.PubMedGoogle Scholar
  9. 9.
    Harris J, Ryan L, Adams G, et al. Survival and relapse in adjuvant autologous tumour vaccine therapy for Dukes B and C colon cancer-EST 5283. Proc Am Soc Clin Oncol 1994: 13:294.Google Scholar
  10. 10.
    Vemorken JB, Claessen AM, van Tinteren H, et al. Active specific immunotherapy for stage I and stage II human colon cancer: a randomized trial. Lancet 1999; 353:345–350.CrossRefGoogle Scholar
  11. 11.
    Odogwu L, Gulley J, Arlen P, Marshall JL. Vaccines for the treatment of cancer. In: Handbook on anticancer pharmacokinetics and pharmacodynamics. Figg WD and McLeod HL, eds. Totowa, NJ: Humana Press, 2004.Google Scholar
  12. 12.
    Maxwell-Armstrong CA, Durrant LG, Scholefield JH. Colorectal cancer vaccines. Br J Surg 1998; 85:149–154.PubMedCrossRefGoogle Scholar
  13. 13.
    Morse MA. Technology evaluation: CEA-TRICOM, Therion Biologics Corp. Curr Opin Mol Ther 2001; 3:407–412.PubMedGoogle Scholar
  14. 14.
    Tsang KY, Zaremba S, Nieroda CA, et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from cancer patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995; 87:982–990.PubMedCrossRefGoogle Scholar
  15. 15.
    McAneny D, Ryan CA, Beazley RN, Kaufman HL. Results of phase I trials of recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced cancer. Ann Surg Oncol 1996; 3:495–500.PubMedCrossRefGoogle Scholar
  16. 16.
    Marshall JL, Hawkins MJ, Tsang KY, et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol 1999; 17: 332–337.PubMedGoogle Scholar
  17. 17.
    Zaremba S, Barzaga E, Zhu MZ, Soares N, Tsang KY, Schlom J. Identification of an enhancer agonist CTL peptide from human carcinoembryonic antigen. Cancer Res 1997; 57:4570.PubMedGoogle Scholar
  18. 18.
    Hodge JW, Sabzevari H, Gomez A, et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999; 59:5800–5807.PubMedGoogle Scholar
  19. 19.
    Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified primeand-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000; 18:3964–3973.PubMedGoogle Scholar
  20. 20.
    Marshall JL, Tsang K, Arlen P, Ley L, Slack R, Toomey M, Chang P, Schlom J. Phase I trial to determine the toxicity and immunologic efficacy of the addition of GM-CSF (GM) and IL-2 to the combination of vaccinia-CEA (V) and Alvac-CEA (A) administered as a prime and boost in patients (potassium) with advanced CEA-bearing cancers. Proc Am Soc Clin Oncol 2001; 272a:108.Google Scholar
  21. 21.
    VonMehren M, Davey V, Rivera G, et al. Phase I trial of ALVAC-CEAB7.1 immunization in advanced CEA-expressing adenocarcinomas. Proc Am Assoc Clin Oncol 1998; 18:1686.Google Scholar
  22. 22.
    Marshall JL, Arlene PM, Rizvi N, Gulley J, Fox E, Hwang J, Tsang K, Schlom J. A Phase I study of sequential vaccinations with fowlpox-CEA (6D)-Tricom (B7/ICAM/LFA3) alone, and in combination with vaccinia-CEA (6D)-Tricom and GM-CSF in patients with CEA expressing carcinomas. Proc Am Soc Clin Oncol 2002; 7a:24.Google Scholar
  23. 23.
    Barnd DL, Lans MS, Metzgar RS, Finn OJ. Specific MHC-unrestricted recognition of tumour-associated mucine by human CTL. Proc Natl Acad Sci USA 1989; 86:7159–7163.PubMedCrossRefGoogle Scholar
  24. 24.
    Karanikas V, Hwang L, Pearson J, et al. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 1997; 100:2783–2792.PubMedCrossRefGoogle Scholar
  25. 25.
    MacLean GD, Reddish MA, Kogantry RR, Longnecker BM. Antibodies against mucin-associated Sialy 1 -Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother 1996; 19:59–68.CrossRefGoogle Scholar
  26. 26.
    Goydos JS, Elder E, Whiteside TL, Finn OJ, et al. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 1996; 63:298–304.PubMedCrossRefGoogle Scholar
  27. 27.
    Akagi J, Hodge JW, McLaughlin JP, et al. Therapeuitc anti-tumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7. J Immunother 1997; 20:38–47.PubMedCrossRefGoogle Scholar
  28. 28.
    Tanaka Y, Kooido S, Chen D, et al. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin Immunol 2001; 101:192–200.PubMedCrossRefGoogle Scholar
  29. 29.
    Yamaguchi A, Ishida T, Nishimura G, Kumaki T, Katoh M, Kosaka T, Yonemura Y, Miyazaki I. Human chorionic gonadotropin in colorectal cancer and its relationship to prognosis. Br J Cancer 1989; 60: 382–384.PubMedCrossRefGoogle Scholar
  30. 30.
    Triozzi PL, Martin EW, Gochnour D, et al. Phase Ib trial of a synthetic beta human chorionic gonadotropin vaccine in patients with metastatic cancer. Ann N Y Acad Sci 1993; 690:358–359.PubMedCrossRefGoogle Scholar
  31. 31.
    Triozzi PL, Stevens VC, Aldrich W, et al. Effects of a beta-human chorionic gonadotropin subunit immunogen administered in aqueous solution with a novel nonionic block copolymer adjuvant in patients with advanced cancer. Clin Cancer Res 1997; 3:2355–2362.PubMedGoogle Scholar
  32. 32.
    Moulton HM, Yoshihara PH, Mason DH, et al. Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival. Clin Cancer Res 2002; 8:2044–2051.PubMedGoogle Scholar
  33. 33.
    Iversen P, Yoshihara P, Moulton H, Engelhart L, Mason DH, Marshall JL. Active beta-hCG specific immunotherapy in patients with pancreatic cancer. Pro Am Soc Clin Oncol 2002; 25a:96.Google Scholar
  34. 34.
    Watson SA, Gilliam AD. G17DT-a new weapon in the therapeutic armoury for gastrointestinal malignancy. Expert Opin Biol Ther 2001; 1:309–317.PubMedCrossRefGoogle Scholar
  35. 35.
    Brett BT, Smith SC, Bouvier CV, et al: Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol 2002; 20:4225–4231.PubMedCrossRefGoogle Scholar
  36. 36.
    Jerne NK. Towards a network theory of the immune system. Ann Immunol 1974; 125C:373–389.Google Scholar
  37. 37.
    Chatterjee SK, Tripathi PK, Chakraborty M, et al. Molecular mimicry of carcinoembryonic antigen by peptides derived from the structure of an anti-idiotype antibody. Cancer Res 1998; 58:1217–1224.PubMedGoogle Scholar
  38. 38.
    Foon KA, Chakraborty M, John WJ, et al. Immune response to carcinoembryonic antigen in patients treated with anti-idiotype antibody vaccine. J Clin Invest 1995; 96:334–342.PubMedCrossRefGoogle Scholar
  39. 39.
    Foon KA, John WJ, Chakraborty M, et al. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics carcinoembryonic antigen. J Clin Oncol 1999; 17:2889–2895.PubMedGoogle Scholar
  40. 40.
    Spendlove I, Li L, Charmichael J, Durrant LG. Decay accelerating factor (CD55): a target for cancer vaccines? Cancer Res 1999; 59:2282–2286.PubMedGoogle Scholar
  41. 41.
    Buckley DT, Robins AR, Durrant LG. Clinical evidence that human monoclonal anti-idiotypic antibody 105AD7, delays tumor growth by stimulating anti-tumor T-cell responses. Hum Antibodies Hybridomas 1995: 6:68–72.PubMedGoogle Scholar
  42. 42.
    Maxwell-Armstrong CA, Durrant LG, Robins RA, et al. Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotypic monoclonal antibody 105AD7. Gut 1999; 45:593–598.PubMedCrossRefGoogle Scholar
  43. 43.
    Ragnhammer P, Fagerberg J, Frodin JE, et al. Effect of monoclonal antibody 17–1A and GM-CSF in patients with advanced colorectal carcinoma-long lasting complete remissions can be induced. Int J Cancer 1993; 53:751–758.CrossRefGoogle Scholar
  44. 44.
    Riethmuller G, Holz E, Schlimok G, et al. Monoclonal antibody therapy for resected Dukes’ C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998; 16:1788–1794.PubMedGoogle Scholar
  45. 45.
    Fields ALA, Keller AM, Schwartzberg S, et al. Edrecolomab in combination with 5-FU based chemotherapy in the adjuvant treatment of stage III colon cancer: results of a randomized North American phase III study. Proc Am Assoc Clin Cancer Res 2002; 21:508.Google Scholar
  46. 46.
    Khleif SN, Abrams SI, Hamilton JM, et al. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors. J Immunother 1999; 22:155–165.PubMedCrossRefGoogle Scholar
  47. 47.
    Behrens RJ, Bernstein SA, Edison M, et al. Phase I/II pilot trial of adjuvant therapy in pancreatic and colorectal cancer patients with mutant ras vaccine. Proc Am Assoc Clin Oncol 2002; 21:112.Google Scholar
  48. 48.
    Mori M, Move H, Mimori K, et al. Expression of MAGE genes in human colorectal carcinoma. Ann Surg 1996; 224:183–188.PubMedCrossRefGoogle Scholar
  49. 49.
    Hasegawa H, Mori M, Heraguchi M, et al. Expression spectrum of melanoma antigen-encoding gene family members in colorectal carcinoma. Arch Pathol Lab Med 1998; 122:551–554.PubMedGoogle Scholar
  50. 50.
    Sadanaga N, Nagashima H, Mashino K, et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 2001; 7:2277–2284.PubMedGoogle Scholar
  51. 51.
    Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG. Altered peptide ligand vaccination with F1t3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 2001; 98:8809–8814.PubMedCrossRefGoogle Scholar
  52. 52.
    Morse MA, Deng Y, Coleman D, Hull S, Kitrell-Fisher E, Nair S, Schlom J, Ryback ME, Lyerly HK. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999; 5:1331–1338.PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2004

Authors and Affiliations

  • John L. Marshall

There are no affiliations available

Personalised recommendations